Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruiting
NCT06498635Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIB Lung Cancer AJCC v8
United States
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartRecruiting
NCT06935370Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Heart Failure
United States, Argentina, Belgium, Brazil, Bulgaria +24 more
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruiting
NCT07480356Phase 3Updated Aug 21, 2026
Sponsor: Protara Therapeutics
Bladder (Urothelial, Transitional Cell) Cancer · Non-Muscle Invasive Bladder Carcinoma · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
United States, Ukraine
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruiting
NCT07195695Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeRecruiting
NCT07153471Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Osteoarthritis
United States, Canada, China, Germany, India +3 more
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Recruiting
NCT07466316Phase 3Updated Aug 21, 2026
Sponsor: Children's Oncology Group
Rhabdomyosarcoma
United States, Canada
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)Recruiting
NCT07778316Phase 3Updated Aug 21, 2026
Sponsor: Amgen
Small Cell Lung Cancer
United States, China
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Recruiting
NCT06997497Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Colon Adenocarcinoma · Rectal Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +24 more
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruiting
NCT07562152Phase 3Updated Aug 21, 2026
Sponsor: Immuneering Corporation
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma
United States, Australia
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruiting
NCT07220252Phase 2, Phase 3Updated Aug 21, 2026
Sponsor: TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
Poland
Adjuvant Steroid Outcomes in Idiopathic Subglottic StenosisRecruiting
NCT07228104Phase 3Updated Aug 21, 2026
Sponsor: Johns Hopkins University
Idiopathic Subglottic Stenosis
United States
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Recruiting
NCT06717347Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +30 more
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Recruiting
NCT07116967Phase 3Updated Aug 21, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
United States, Argentina, Australia, Belgium, Brazil +20 more
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruiting
NCT07391774Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8 · Estrogen Receptor-Positive Breast Carcinoma
United States, Puerto Rico
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigraineRecruiting
NCT07018700Phase 3Updated Aug 21, 2026
Sponsor: Merz Therapeutics GmbH
Episodic Migraine
United States, Austria, Canada, Czechia, Denmark +8 more
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Recruiting
NCT07221253Phase 3Updated Aug 21, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Belgium, Brazil, Canada +14 more
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsRecruiting
NCT06499285Phase 3Updated Aug 21, 2026
Sponsor: Takeda
Myelodysplastic Syndromes
United States, Australia, Brazil, Bulgaria, Canada +21 more
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)Recruiting
NCT07210515Phase 3Updated Aug 21, 2026
Sponsor: Ambros Therapeutics, Inc.
Complex Regional Pain Syndrome Type I
United States
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Recruiting
NCT06430801Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Crohn's Disease
United States, Australia, Austria, Belgium, Brazil +42 more
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDRecruiting
NCT06847542Phase 3Updated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Austria, Czechia, Denmark, France, Germany +8 more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisRecruiting
NCT05878860Phase 3Updated Aug 21, 2026
Sponsor: Atsena Therapeutics Inc.
X-linked Retinoschisis
United States, United Kingdom
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical ThrombectomyRecruiting
NCT07727395Phase 3Updated Aug 21, 2026
Sponsor: 115 People's Hospital
Stroke, Acute Ischemic · Large Vessel Occlusion · Thrombectomy
Vietnam
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruiting
NCT06617325Phase 3Updated Aug 21, 2026
Sponsor: UCB Biopharma SRL
Systemic Lupus Erythematosus
United States, Argentina, Belgium, Canada, Chile +17 more

Previous page Next page